Haemonetics Corporation

Total Valuation

Haemonetics Corporation carries a market capitalization of 4.68B, placing it among publicly traded companies globally. Its enterprise value stands at 4.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Haemonetics Corporation currently has 45.47M shares outstanding.

Valuation Ratios

Haemonetics Corporation trades at a trailing price-to-earnings ratio of 36.21. The price-to-sales ratio is 2.58, and the price-to-book ratio stands at 4.07.

Enterprise Valuation

On an enterprise value basis, Haemonetics Corporation trades at an EV/EBITDA multiple of 12.28 and an EV/FCF ratio of 12.45. The EV/Sales ratio of 3.23 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.80 provides insight into valuation relative to core operating earnings.

Financial Position

Haemonetics Corporation maintains a current ratio of 3.08, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 140.26, indicating elevated leverage, while an interest coverage ratio of 11.88 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Haemonetics Corporation posts a return on equity of 11.20 and a return on invested capital of 8.80.

Taxes

Over the trailing twelve months, Haemonetics Corporation has paid 34.15M in income taxes, reflecting an effective tax rate of 26.18.

Stock Price Statistics

Haemonetics Corporation's stock has gained approximately 90.31065% over the past 52 weeks. The 50-day moving average sits at 87.23, while the 200-day moving average is 72.55.

Income Statement

Over the trailing twelve months, Haemonetics Corporation generated 1.35B in revenue and converted that into 96.29M in net income, yielding earnings per share of 2.06. EBITDA reached 355.06M, while operating income came in at 244.99M.

Balance Sheet

Haemonetics Corporation holds 223.38M in cash and equivalents against 1.17B in total debt, resulting in a net debt position of 950.77M. Total book value stands at 837.10M, with working capital of 547.60M providing operational flexibility.

Cash Flow

Haemonetics Corporation produced 328.15M in operating cash flow over the past twelve months.

Margins

Haemonetics Corporation operates with a gross margin of 59.03, reflecting its pricing power and cost economics. The operating margin of 18.12 and net profit margin of 7.12 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Haemonetics Corporation's most recent stock split took place on December 3, 2012 with a 1:2 split ratio.

Scores

Haemonetics Corporation posts an Altman Z-Score of 3.89, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.